OpGen Announces Results of Special Meeting of Stockholders
December 08 2021 - 4:30PM
OpGen, Inc. (Nasdaq: OPGN, “OpGen” or the “Company”), a precision
medicine company harnessing the power of molecular diagnostics and
informatics to help combat infectious disease, today announced that
stockholders have approved the two proposals voted on at the
Company’s Special Meeting of Stockholders held on December 8, 2021.
The first proposal was to reduce the stockholder
approval requirement for changes to the Company’s Amended and
Restated Certificate of Incorporation, as amended (the “Charter”),
to a majority of the outstanding shares entitled to vote. The
second proposal was an amendment to the Charter to increase the
authorized number of shares of common stock from 50 million to 100
million. On proposal one, approximately 99.3% of the outstanding
voting power of the Company’s capital stock voted in favor of the
proposal. Of the shares of common stock voted on proposal two,
approximately 79.8% voted in favor of the second proposal. As
described in the Company’s Definitive Proxy Statement filed with
the Securities and Exchange Commission on October 29, 2021, the
total votes represented by shares of the Company’s Series B
Convertible Preferred Stock that were voted on proposal two were
automatically counted by the Company in the same proportion as the
shares of common stock voted on the proposal. Accordingly,
approximately 79.8% of the votes represented by such shares of
preferred stock were counted in favor of proposal two.
OpGen’s Chief Executive Officer, Oliver Schacht,
commented, "We are very pleased that our stockholders strongly
supported and voted to approve of these important matters. By
successfully increasing the authorized number of shares, the
Company achieved a critical milestone in its efforts to maintain
flexibility and capacity to raise additional capital, when
appropriate, for future growth and development.”
About OpGen, Inc.
OpGen, Inc. (Rockville, MD, USA) is a precision
medicine company harnessing the power of molecular diagnostics and
bioinformatics to help combat infectious disease. Along with
subsidiaries, Curetis GmbH and Ares Genetics GmbH, we are
developing and commercializing molecular microbiology solutions
helping to guide clinicians with more rapid and actionable
information about life threatening infections to improve patient
outcomes, and decrease the spread of infections caused by
multidrug-resistant microorganisms, or MDROs. OpGen’s product
portfolio includes Unyvero®, Acuitas® AMR Gene Panel and the ARES
Technology Platform including ARESdb®, using NGS technology and
AI-powered bioinformatics solutions for antibiotic response
prediction.
For more information, please visit
www.opgen.com.
Forward-Looking Statements
This press release includes statements regarding
the results of OpGen’s Special Meeting of Stockholders. These
statements and other statements regarding OpGen’s future plans and
goals constitute "forward-looking statements" within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934 and are intended to qualify for the
safe harbor from liability established by the Private Securities
Litigation Reform Act of 1995. Such statements are subject to risks
and uncertainties that are often difficult to predict, are beyond
our control, and which may cause results to differ materially from
expectations. Factors that could cause our results to differ
materially from those described include, but are not limited to,
our ability to successfully, timely and cost-effectively develop,
seek and obtain regulatory clearance for and commercialize our
product and services offerings, the rate of adoption of our
products and services by hospitals and other healthcare providers,
the fact that we may not effectively use proceeds from recent
financings, the realization of expected benefits of our business
combination transaction with Curetis GmbH, the success of our
commercialization efforts, the impact of COVID-19 on the Company’s
operations, financial results, and commercialization efforts as
well as on capital markets and general economic conditions, the
effect on our business of existing and new regulatory requirements,
and other economic and competitive factors. For a discussion of the
most significant risks and uncertainties associated with OpGen's
business, please review our filings with the Securities and
Exchange Commission. You are cautioned not to place undue reliance
on these forward-looking statements, which are based on our
expectations as of the date of this press release and speak only as
of the date of this press release. We undertake no obligation to
publicly update or revise any forward-looking statement, whether as
a result of new information, future events or otherwise.
OpGen:Oliver SchachtPresident and
CEOInvestorRelations@opgen.com
OpGen Press Contact:Matthew
Bretzius FischTank Marketing and PR
matt@fischtankpr.com
OpGen Investor Contact:Maxwell
ColbertEdison
Group mcolbert@edisongroup.com
OpGen (NASDAQ:OPGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
OpGen (NASDAQ:OPGN)
Historical Stock Chart
From Jul 2023 to Jul 2024